1.

EGFR-TKIs治疗NSCLC脑转移患者的临床试验和研究

Trials and studies about the treatment of EGFR-TKIs for NSCLC patients with brain metastases

Author	Year	N	Pts selection	Prior treatment	Treatment	ORR (%)	DCR (%)	PFS (mo)	OS (mo)
N: number; Pts: patients; ORR: objective response rate; DCR: disease control rate; PFS: progression free survival; OS: overall survival; WBRT: whole brain radiotherapy; NA: not available; EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC: non-small cel l lung cancer.
Ceresoli et al[16]	2004	41	Unknown	Chemotherapy or WBRT	Gefitinib	10.0	27.0	3.0	5.0
Hotta et al[17]	2004	14	Unknown	No	Gefitinib	42.9	100	7.7	9.9
Namba et al[18]	2004	15	Unknown	No	Gefitinib	60.0	67.7	NA	8.3
Kim et al[19]	2009	23	No smoker	No	Gefitinib	69.6	82.6	7.1	18.8
Porta et al[20]	2011	17	EGFR mutated	No	Erlotinib	82.4	90.0	11.7	12.9
Park et al[21]	2012	28	EGFR mutated	No	Erlotinb	83.0	93.0	6.6	15.9
Welsh et al[24]	2013	40	Unknown	WBRT	Erlotinib	86.0	NA	9.3	11.8
Iuchi et al[22]	2013	41	EGFR mutated	No	Gefitinib	87.8	NA	14.5	21.9
Song et al[23]	2014	103	EGFR mutated	Radiotherapy	Gefitinib	11.7	53.4	9.0	NA